CENTANAFADINE SR IS A NOREPINEPHRINE- AND DOPAMINE-PREFERRING TRIPLE REUPTAKE INHIBITOR THAT HAS THE RIGHT RATIO FOR THE RIGHT PATIENT
Case File Statements
GS0051: Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for neurological use, Attention Deficit Hyperactivity Disorder, psychiatric diseases and disorders, all of which contain a compound that is a norepinephrine and dopamine-preferring triple reuptake inhibitor
Case File Event Statements
7/9/2018 - 6 years ago
48 - ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDType:MAB6
7/9/2018 - 6 years ago
47 - ABANDONMENT - NO USE STATEMENT FILEDType:ABN6
12/8/2017 - 7 years ago
46 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILEDType:EXRA
12/7/2017 - 7 years ago
45 - EXTENSION 5 GRANTEDType:EX5G
12/1/2017 - 7 years ago
44 - EXTENSION 5 FILEDType:EXT5
12/7/2017 - 7 years ago
43 - CASE ASSIGNED TO INTENT TO USE PARALEGALType:AITU
12/1/2017 - 7 years ago
42 - TEAS EXTENSION RECEIVEDType:EEXT
6/6/2017 - 7 years ago
41 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILEDType:EXRA
6/2/2017 - 7 years ago
40 - EXTENSION 4 GRANTEDType:EX4G
6/2/2017 - 7 years ago
39 - EXTENSION 4 FILEDType:EXT4
6/2/2017 - 7 years ago
38 - TEAS EXTENSION RECEIVEDType:EEXT
12/20/2016 - 8 years ago
37 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILEDType:EXRA
12/19/2016 - 8 years ago
36 - EXTENSION 3 GRANTEDType:EX3G
12/2/2016 - 8 years ago
35 - EXTENSION 3 FILEDType:EXT3
12/2/2016 - 8 years ago
34 - TEAS EXTENSION RECEIVEDType:EEXT
7/9/2016 - 8 years ago
33 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILEDType:EXRA
7/8/2016 - 8 years ago
32 - EXTENSION 2 GRANTEDType:EX2G
6/2/2016 - 8 years ago
31 - EXTENSION 2 FILEDType:EXT2
7/5/2016 - 8 years ago
30 - CASE ASSIGNED TO INTENT TO USE PARALEGALType:AITU